These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 29516230)

  • 21. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials.
    Zannad F; Ferreira JP; Pocock SJ; Anker SD; Butler J; Filippatos G; Brueckmann M; Ofstad AP; Pfarr E; Jamal W; Packer M
    Lancet; 2020 Sep; 396(10254):819-829. PubMed ID: 32877652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronic heart failure].
    Hradec J
    Cas Lek Cesk; 2015; 154(6):260-8. PubMed ID: 26750621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction.
    Shen L; Rørth R; Cosmi D; Kristensen SL; Petrie MC; Cosmi F; Latini R; Køber L; Anand IS; Carson PE; Granger CB; Komajda M; McKelvie RS; Solomon SD; Staszewsky L; Swedberg K; Huynh T; Zile MR; Jhund PS; McMurray JJV
    Eur J Heart Fail; 2019 Aug; 21(8):974-984. PubMed ID: 31271255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Type 2 Diabetes Mellitus and Heart Failure: Innovative Possibilities for Management of Prognosis].
    Kobalava ZD; Yeshniyazov NV; Medovchshikov VV; Khasanova ER
    Kardiologiia; 2019 Apr; 59(4):76-87. PubMed ID: 31002044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
    Wolsk E; Claggett B; Køber L; Pocock S; Yusuf S; Swedberg K; McMurray JJV; Granger CB; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2018 Mar; 20(3):504-510. PubMed ID: 29193462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis.
    Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J
    Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes.
    McHugh KR; DeVore AD; Mentz RJ; Edmonston D; Green JB; Hernandez AF
    Clin Cardiol; 2018 Sep; 41(9):1259-1267. PubMed ID: 30125365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 30. Eligibility for sotagliflozin in a real-world heart failure population based on the SOLOIST-WHF trial enrolment criteria: data from the Swedish heart failure registry.
    Becher PM; Savarese G; Benson L; Dahlström U; Karlström P; Mol PGM; Metra M; Bhatt DL; Pitt B; Lund LH
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):343-352. PubMed ID: 36718512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes.
    Cosmi F; Shen L; Magnoli M; Abraham WT; Anand IS; Cleland JG; Cohn JN; Cosmi D; De Berardis G; Dickstein K; Franzosi MG; Gullestad L; Jhund PS; Kjekshus J; Køber L; Lepore V; Lucisano G; Maggioni AP; Masson S; McMurray JJV; Nicolucci A; Petrarolo V; Robusto F; Staszewsky L; Tavazzi L; Teli R; Tognoni G; Wikstrand J; Latini R
    Eur J Heart Fail; 2018 May; 20(5):888-895. PubMed ID: 29488676
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review.
    Jhalani NB
    Adv Ther; 2022 Aug; 39(8):3472-3487. PubMed ID: 35699903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failure.
    Sharma A; Wu J; Ezekowitz JA; Felker GM; Udell JA; Heidenreich PA; Fonarow GC; Mahaffey KW; Hernandez AF; DeVore AD
    ESC Heart Fail; 2020 Feb; 7(1):274-278. PubMed ID: 31747132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Fragasso G; Petrie M; Mullens W; Ferrari R; Thum T; Bauersachs J; Anker SD; Ray R; Çavuşoğlu Y; Polovina M; Metra M; Ambrosio G; Prasad K; Seferović J; Jhund PS; Dattilo G; Čelutkiene J; Piepoli M; Moura B; Chioncel O; Ben Gal T; Heymans S; de Boer RA; Jaarsma T; Hill L; Lopatin Y; Lyon AR; Ponikowski P; Lainščak M; Jankowska E; Mueller C; Cosentino F; Lund L; Filippatos GS; Ruschitzka F; Coats AJS; Rosano GMC
    Eur J Heart Fail; 2020 Sep; 22(9):1495-1503. PubMed ID: 32618086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials.
    Lu Y; Li F; Fan Y; Yang Y; Chen M; Xi J
    Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of antihyperglycemic therapies on cardiovascular and heart failure outcomes: an updated meta-analysis and meta-regression analysis of 35 randomized cardiovascular outcome trials.
    Hasebe M; Yoshiji S; Keidai Y; Minamino H; Murakami T; Tanaka D; Fujita Y; Harada N; Hamasaki A; Inagaki N
    Cardiovasc Diabetol; 2023 Mar; 22(1):62. PubMed ID: 36935489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Empagliflozin: A Review in Symptomatic Chronic Heart Failure.
    Frampton JE
    Drugs; 2022 Nov; 82(16):1591-1602. PubMed ID: 36374374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization.
    Khan MS; Fonarow GC; McGuire DK; Hernandez AF; Vaduganathan M; Rosenstock J; Handelsman Y; Verma S; Anker SD; McMurray JJV; Kosiborod MN; Butler J
    Circulation; 2020 Sep; 142(12):1205-1218. PubMed ID: 32955939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized controlled trials.
    Kongmalai T; Hadnorntun P; Leelahavarong P; Kongmalai P; Srinonprasert V; Chirakarnjanakorn S; Chaikledkaew U; McKay G; Attia J; Thakkinstian A
    Front Endocrinol (Lausanne); 2023; 14():1216160. PubMed ID: 38179304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diabetes mellitus and heart failure: an update on pathophysiology and therapy.
    Potere N; Del Buono MG; Vecchié A; Porreca E; Abbate A; Dentali F; Bonaventura A
    Minerva Cardiol Angiol; 2022 Jun; 70(3):344-356. PubMed ID: 35212512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.